India, July 16 -- CareDx, Inc. (CDNA) shares surged more than 20% after the company announced the finalization of the Medicare Local Coverage Determination (LCD) for molecular testing in solid organ transplant rejection. In addition, CareDx said it will report second-quarter results on July 30, 2026.
The final Medicare policy affirms coverage for surveillance testing used to detect early organ rejection in kidney, heart and lung transplant recipients.
CareDx is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and provides genomics-based information for tra...